{"id":4451,"date":"2022-08-15T18:07:25","date_gmt":"2022-08-15T18:07:25","guid":{"rendered":"https:\/\/cdhf2022.local\/quebec-biosimilars-initiative\/"},"modified":"2025-06-18T14:30:34","modified_gmt":"2025-06-18T14:30:34","slug":"quebec-biosimilars-initiative","status":"publish","type":"post","link":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/","title":{"rendered":"Initiative qu\u00e9b\u00e9coise sur les biosimilaires"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\" id=\"what-is-changing\"><strong>Qu\u2019est-ce qui a chang\u00e9 dans la couverture des m\u00e9dicaments biologiques du Qu\u00e9bec?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Le 18 mai 2021, le ministre de la Sant\u00e9 et des Services sociaux, Christian Dub\u00e9, a annonc\u00e9 que le gouvernement du Qu\u00e9bec lan\u00e7ait une initiative sur les biosimilaires qui consiste \u00e0 faire passer les patients des m\u00e9dicaments biologiques d&#8217;origine \u00e0 leurs versions biosimilaires. Elle fait suite \u00e0 la mise en \u0153uvre r\u00e9ussie d&#8217;initiatives similaires par la Colombie-Britannique et l&#8217;Alberta. En outre, le passage aux biosimilaires a \u00e9t\u00e9 largement men\u00e9 en Europe, o\u00f9 les pays ont plus de 15 ans d&#8217;exp\u00e9rience avec les biosimilaires.  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Depuis le 12 avril 2022, le r\u00e9gime d&#8217;assurance maladie du Qu\u00e9bec (RAMQ) couvre uniquement l&#8217;utilisation des biosimilaires suivants, utilis\u00e9s pour traiter la maladie de Crohn et la colite ulc\u00e9reuse :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Inflectra\u00ae, Renflexis\u2122 et Avosola\u2122 <strong>(biosimilaires de Remicade\u00ae)<\/strong>.<\/li>\n\n\n\n<li>Idacio\u00ae, Amgevita\u2122, Hadlima\u00ae, Hyrimoz\u00ae, Hulio\u00ae <strong>(biosimilaires de <sup>Humira\u00ae<\/sup>)<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.msss.gouv.qc.ca\/ministere\/salle-de-presse\/communique-2864\/\">Lire la d\u00e9claration publi\u00e9e le 18 mai 2021 par le minist\u00e8re de la Sant\u00e9 et des Services sociaux du Qu\u00e9bec au sujet de l&#8217;initiative sur les biosimilaires.<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">L&#8217;essor des biosimilaires dans le secteur de la sant\u00e9 au Canada :  <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">L&#8217;essor des produits biologiques et biosimilaires au Canada a entra\u00een\u00e9 une hausse vertigineuse des co\u00fbts des r\u00e9gimes d&#8217;assurance-m\u00e9dicaments, qui ne semble pas pr\u00e8s de s&#8217;att\u00e9nuer. Les biosimilaires sont des anticorps cr\u00e9\u00e9s en laboratoire \u00e0 partir de cellules vivantes qui emp\u00eachent certaines prot\u00e9ines de l&#8217;organisme de provoquer une inflammation, ce qui permet de soulager les sympt\u00f4mes inconfortables des MICI. Cependant, les biosimilaires permettent de r\u00e9aliser jusqu&#8217;\u00e0 50 % d&#8217;\u00e9conomies tout en offrant des avantages \u00e9quivalents en termes de sant\u00e9. La Colombie-Britannique a ouvert la voie \u00e0 l&#8217;adoption de biosimilaires, ce qui a permis d&#8217;\u00e9conomiser des millions de dollars. Ce changement intervient parce que les biosimilaires \u00e0 l&#8217;\u00e9chelle nationale pourraient permettre d&#8217;\u00e9conomiser des milliards de dollars, all\u00e9geant ainsi la pression sur le syst\u00e8me de soins de sant\u00e9. Pour en savoir plus, regardez la vid\u00e9o ci-dessous.  <\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"L\u2019essor des biosimilaires dans les soins de sant\u00e9 au Canada\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/F8SgsPZ9qC8?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Nouveaux patients :  <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Si vous venez de recevoir un diagnostic de MICI, votre m\u00e9decin vous a peut-\u00eatre recommand\u00e9 de commencer un traitement biologique. Qu&#8217;est-ce que cela signifie ? Les m\u00e9dicaments biologiques sont des anticorps cr\u00e9\u00e9s en laboratoire \u00e0 partir de cellules vivantes qui emp\u00eachent certaines prot\u00e9ines de l&#8217;organisme de provoquer une inflammation. Les biosimilaires sont cr\u00e9\u00e9s selon le m\u00eame processus que le produit biologique original, sans diff\u00e9rence cliniquement significative en termes de s\u00e9curit\u00e9 et d&#8217;efficacit\u00e9. Le CDHF sait qu&#8217;il peut \u00eatre tr\u00e8s stressant de commencer \u00e0 prendre un m\u00e9dicament. Regardez la vid\u00e9o ci-dessous pour en savoir plus.  <\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Un guide pour la transition vers la th\u00e9rapie biologique pour les MII\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/fj1KqKvulJM?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Patients en transition :  <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">425 000 Canadiens vivent avec une maladie <a href=\"https:\/\/cdhf.ca\/fr\/digestive-conditions\/ibd-crohns-disease\/\">inflammatoire de l&#8217;intestin (MII)<\/a>. Si vous en faites partie, votre m\u00e9decin vous a peut-\u00eatre sugg\u00e9r\u00e9 de passer d&#8217;un produit biologique \u00e0 un produit biosimilaire. Sant\u00e9 Canada confirme l&#8217;efficacit\u00e9 et la s\u00e9curit\u00e9 des biosimilaires, en assurant qu&#8217;il n&#8217;y a pas de diff\u00e9rences attendues en termes d&#8217;efficacit\u00e9 ou de s\u00e9curit\u00e9 par rapport au m\u00e9dicament biologique de r\u00e9f\u00e9rence.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le passage \u00e0 l&#8217;euro permet d&#8217;am\u00e9liorer les soins aux patients, les \u00e9conomies r\u00e9alis\u00e9es \u00e9tant affect\u00e9es au d\u00e9veloppement des m\u00e9dicaments subventionn\u00e9s, \u00e0 l&#8217;am\u00e9lioration de l&#8217;acc\u00e8s des patients et \u00e0 l&#8217;avancement de nouveaux traitements m\u00e9dicaux. Au CDHF, nous comprenons le stress li\u00e9 au changement de m\u00e9dicaments. Explorez notre <a href=\"https:\/\/cdhf.ca\/fr\/biosimilar-library\/\">biblioth\u00e8que sur les biosimilaires<\/a> pour trouver des ressources informatives qui vous permettront d&#8217;effectuer une transition en douceur vers votre nouveau traitement. Regardez la vid\u00e9o ci-dessous pour en savoir plus.  <\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Le paysage des MII\u00a0:l\u2019impact des biosimilaires sur le co\u00fbt, les soins et l\u2019avenir des soins de sant\u00e9\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/PzE8RI6VR-I?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"block-07b5a1d5-7844-4a10-b370-8a9f6f13c375\"><strong>Questions fr\u00e9quemment pos\u00e9es<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"block-a0dfe8f8-cb92-4f67-ae3e-b0a415226f24\"><strong>1. Qu&#8217;est-ce qu&#8217;un produit biologique ?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"block-2e5e9d2f-ed8a-4b7e-b73f-09a00a57146f\">Les m\u00e9dicaments biologiques (de r\u00e9f\u00e9rence) sont des m\u00e9dicaments fabriqu\u00e9s \u00e0 partir d&#8217;organismes vivants (tels que des levures ou des cellules animales) pour produire des prot\u00e9ines complexes qui sont purifi\u00e9es puis administr\u00e9es afin d&#8217;agir sur certains processus du corps humain.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"block-e1c8bb33-426b-44c0-905a-f1446eacaacd\"><strong>2. Qu&#8217;est-ce qu&#8217;un biosimilaire ?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"block-eb42b986-e5f5-4157-a496-53cc2f09964c\">Un biosimilaire est un m\u00e9dicament dont il a \u00e9t\u00e9 d\u00e9montr\u00e9 qu&#8217;il est tr\u00e8s similaire \u00e0 un m\u00e9dicament biologique (de r\u00e9f\u00e9rence) et dont la vente a \u00e9t\u00e9 autoris\u00e9e au Canada.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"block-5b7121b1-91b7-410e-80b2-cdd662e9f76b\"><strong>3. Que disent les experts de la s\u00e9curit\u00e9 et de l&#8217;efficacit\u00e9 des biosimilaires ?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"block-88ce1d4e-5864-472f-8a5d-b4aa99681f87\"><a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/fact-sheet-biosimilars.html\">Sant\u00e9 Canada<\/a> est charg\u00e9 de garantir la s\u00e9curit\u00e9, l&#8217;efficacit\u00e9 et la qualit\u00e9 de tous les nouveaux m\u00e9dicaments, y compris les produits biologiques et les biosimilaires. Pour qu&#8217;un m\u00e9dicament biosimilaire soit approuv\u00e9 au Canada, Sant\u00e9 Canada doit constater qu&#8217;il n&#8217;y a pas de diff\u00e9rences significatives en termes de s\u00e9curit\u00e9 et d&#8217;efficacit\u00e9 par rapport au m\u00e9dicament biologique.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"block-5c4ca28d-ca77-41ed-a513-040c64dfdb83\">&#8220;L&#8217;initiative du gouvernement visant \u00e0 accro\u00eetre l&#8217;utilisation des biosimilaires est logique, car il a \u00e9t\u00e9 garanti que les \u00e9conomies r\u00e9alis\u00e9es resteraient dans les r\u00e9gimes publics d&#8217;assurance-m\u00e9dicaments pour financer de nouveaux m\u00e9dicaments. Les biosimilaires sont tout aussi s\u00fbrs et efficaces que les versions originales, comme le d\u00e9montrent les exp\u00e9riences de la Colombie-Britannique, de l&#8217;Alberta et de l&#8217;Europe.  <em><strong>&#8211; Dr Mark MacMillan, gastro-ent\u00e9rologue et professeur adjoint \u00e0 la division des soins digestifs et de l&#8217;endoscopie au d\u00e9partement de m\u00e9decine de l&#8217;universit\u00e9 Dalhousie.<\/strong><\/em><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"block-857fb731-c6e5-477e-9da3-54db29f52909\"><strong>4. Dois-je passer \u00e0 un biosimilaire ?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"block-b235804c-82ee-46f9-9cac-f3f980f2f8c0\">Dans le cadre de l&#8217;initiative sur les biosimilaires, si vous b\u00e9n\u00e9ficiez d&#8217;une couverture au Qu\u00e9bec et que vous prenez actuellement Remicade\u00ae ou Humira<sup>\u00ae<\/sup>pour le traitement de la maladie de Crohn ou de la colite ulc\u00e9reuse, vous devez passer \u00e0 la version biosimilaire avant la fin de la p\u00e9riode de transition (12 avril 2022) pour \u00e9viter toute interruption de votre couverture. Il peut y avoir des raisons m\u00e9dicales pour lesquelles vous ne pouvez pas passer \u00e0 un biosimilaire. Votre m\u00e9decin peut vous aider \u00e0 d\u00e9terminer s&#8217;il est m\u00e9dicalement n\u00e9cessaire de continuer \u00e0 prendre un m\u00e9dicament biologique (de r\u00e9f\u00e9rence) et vous confirmera si vous pouvez b\u00e9n\u00e9ficier d&#8217;une exemption.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"block-6df36632-72f6-4655-b926-20bdab6804b0\"><strong>5. Pourquoi ce changement se produit-il ?<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.msss.gouv.qc.ca\/ministere\/salle-de-presse\/communique-2864\/\">Le ministre de la Sant\u00e9 et des Services sociaux, Christian Dub\u00e9, annonce que le gouvernement du Qu\u00e9bec amorce un virage en faveur de l&#8217;utilisation des m\u00e9dicaments biosimilaires,<\/a> ce qui g\u00e9n\u00e9rera des \u00e9conomies annuelles de plus de 100 millions de dollars, uniquement pour le r\u00e9gime public de sant\u00e9. l&#8217;assurance m\u00e9dicaments et ses assur\u00e9s. Ces \u00e9conomies seront r\u00e9investies dans le syst\u00e8me de sant\u00e9, notamment pour am\u00e9liorer l&#8217;acc\u00e8s aux th\u00e9rapies m\u00e9dicamenteuses innovantes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Malgr\u00e9 l&#8217;inscription de plusieurs m\u00e9dicaments biosimilaires sur les listes de m\u00e9dicaments depuis de nombreuses ann\u00e9es suite aux recommandations de l&#8217;Institut national d&#8217;excellence en sant\u00e9 et services sociaux (INESSS), ils restent sous-utilis\u00e9s. Cette situation engendre un surco\u00fbt consid\u00e9rable pour le r\u00e9gime g\u00e9n\u00e9ral d&#8217;assurance des m\u00e9dicaments puisque les m\u00e9dicaments biosimilaires sont nettement moins chers que les m\u00e9dicaments de r\u00e9f\u00e9rence, sans qu&#8217;il y ait de diff\u00e9rence de traitement pour les patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;L&#8217;innovation est \u00e0 l&#8217;origine d&#8217;avanc\u00e9es m\u00e9dicales incroyables et du d\u00e9veloppement de pratiques et d&#8217;offres de soins toujours mieux adapt\u00e9es aux besoins des personnes. Le virage d\u00e9cisif que nous prenons vers l&#8217;utilisation judicieuse des m\u00e9dicaments biosimilaires en est un bon exemple. Je suis convaincu que cela contribuera \u00e0 assurer la durabilit\u00e9 et la viabilit\u00e9 de notre syst\u00e8me de sant\u00e9. Nous avons \u00e0 c\u0153ur la sant\u00e9 de la population et les actions entreprises dans ce domaine sont dans l&#8217;int\u00e9r\u00eat et au b\u00e9n\u00e9fice des patients&#8221;.  <strong>&#8211; <em>Christian Dub\u00e9, ministre de la Sant\u00e9 et des Services sociaux<\/em><\/strong> <\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"block-2e5e503d-e80f-4dff-8e14-9d15d5f23fa7\"><strong>Liens vers les ressources du CDHF<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/cdhf.ca\/fr\/biosimilar-library\/\">Explorer la biblioth\u00e8que de biosimilaires du CDHF<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cdhf.ca\/fr\/cdhf-talks-your-new-infusion-clinic\/\">#CDHFTalks : Votre nouvelle clinique de perfusion<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cdhf.ca\/en\/biosimilars-for-ibd-making-the-transition\/\">CDHF | Biosimilaires pour les MICI : Webinaire sur la transition<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cdhf.ca\/fr\/whats-health-canada-saying-about-biosimilars-animation\/\">CDHF | Que dit Sant\u00e9 Canada \u00e0 propos de l&#8217;animation sur les biosimilaires ?<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cdhf.ca\/fr\/switching-from-a-biologic-to-a-biosimilar\/\">CDHF | Infographie sur ce que dit Sant\u00e9 Canada \u00e0 propos des biosimilaires<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/cdhf.ca\/fr\/switching-from-a-biologic-to-a-biosimilar\/\">CDHF | IBD : Passer d&#8217;un produit biologique \u00e0 un produit biosimilaire Animation<\/a><\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"block-4d657f10-cd10-43d7-a946-696473032d51\"><strong>En savoir plus<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.msss.gouv.qc.ca\/ministere\/salle-de-presse\/communique-2864\/\">Minist\u00e8re de la Sant\u00e9 et des Services sociaux du Qu\u00e9bec<\/a> <a href=\"https:\/\/www.msss.gouv.qc.ca\/ministere\/salle-de-presse\/communique-2864\/\">Communiqu\u00e9 de presse<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.quebec.ca\/sante\/systeme-et-services-de-sante\/medicaments-biosimilaires\">Informations sur les biosimilaires du minist\u00e8re qu\u00e9b\u00e9cois<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/fact-sheet-biosimilars.html\">Fiche d&#8217;information de Sant\u00e9 Canada sur les biosimilaires<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/information-submission-requirements-biosimilar-biologic-drugs-1.html\">Gouvernement du Canada | Documents d&#8217;orientation : Exigences en mati\u00e8re d&#8217;information et de pr\u00e9sentation pour les m\u00e9dicaments biologiques biosimilaires<\/a><\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"block-3a45b3b9-c856-4340-9dc2-19f67ea2addb\"><strong>Autres ressources pertinentes<\/strong><\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/biosimilaroptions.ca\/\">Groupe de travail sur les biosimilaires<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/biosim.jointhealth.org\/\">\u00c9change de biosimulations<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/biosimilar_drugs_professional_en.pdf\">Fiche d&#8217;information de l&#8217;ACMTS sur les m\u00e9dicaments biosimilaires<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/biosimilar_drugs_professional_en.pdf\">Sant\u00e9 Canada, M\u00e9dicaments biologiques biosimilaires au Canada &#8211; Fiche d&#8217;information<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/information-submission-requirements-biosimilar-biologic-drugs-1.html\">Gouvernement du Canada | Documents d&#8217;orientation : Exigences en mati\u00e8re d&#8217;information et de pr\u00e9sentation pour les m\u00e9dicaments biologiques biosimilaires<\/a><\/li>\n<\/ul>\n\n\n<div class=\"gradient-divider\"><\/div><div class=\"sponsor-block\"><p><p>Cette information a \u00e9t\u00e9 rendue possible gr\u00e2ce \u00e0 un parrainage \u00e9ducatif sans restriction de Sandoz.<\/p><\/p><div class=\"sponsor-details\"><div class=\"photo\" >\n<a target=\"_blank\" href=\"https:\/\/www.sandoz.ca\/fr\"><img decoding=\"async\" class=\"lazyload\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" data-src=\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/11\/sandoz-logo-fr.webp\"  \/><noscript><img decoding=\"async\" class=\"lazyload\" src=\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/11\/sandoz-logo-fr.webp\"  \/><\/noscript><\/a>\n<\/div>\n        <\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Qu\u2019est-ce qui a chang\u00e9 dans la couverture des m\u00e9dicaments biologiques du Qu\u00e9bec? Le 18 mai 2021, le ministre de la Sant\u00e9 et des Services sociaux, Christian Dub\u00e9, a annonc\u00e9 que le gouvernement du Qu\u00e9bec lan\u00e7ait une initiative sur les biosimilaires qui consiste \u00e0 faire passer les patients des m\u00e9dicaments biologiques d&#8217;origine \u00e0 leurs versions biosimilaires. [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":4448,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"cdhf2022_sponsors_meta":[],"footnotes":""},"categories":[113],"tags":[167,157],"class_list":["post-4451","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video-fr","tag-biologics-biosimilars-fr","tag-politique"],"acf":{"article_writer":[3779]},"featured_image_src":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/quebec-biosimilars.webp","author_info":{"display_name":"Sophie Allan","author_link":"https:\/\/cdhf.ca\/fr\/author\/sophie-allen\/"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Initiative qu\u00e9b\u00e9coise sur les biosimilaires - Canadian Digestive Health Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Initiative qu\u00e9b\u00e9coise sur les biosimilaires - Canadian Digestive Health Foundation\" \/>\n<meta property=\"og:description\" content=\"Qu\u2019est-ce qui a chang\u00e9 dans la couverture des m\u00e9dicaments biologiques du Qu\u00e9bec? Le 18 mai 2021, le ministre de la Sant\u00e9 et des Services sociaux, Christian Dub\u00e9, a annonc\u00e9 que le gouvernement du Qu\u00e9bec lan\u00e7ait une initiative sur les biosimilaires qui consiste \u00e0 faire passer les patients des m\u00e9dicaments biologiques d&#8217;origine \u00e0 leurs versions biosimilaires. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Digestive Health Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CDHFdn\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-15T18:07:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-18T14:30:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/quebec-biosimilars.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sophie Allan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TheCDHF\" \/>\n<meta name=\"twitter:site\" content=\"@TheCDHF\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sophie Allan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/\"},\"author\":{\"name\":\"Sophie Allan\",\"@id\":\"https:\/\/cdhf.ca\/fr\/#\/schema\/person\/70d0733e8829dc3d75b25a0395127248\"},\"headline\":\"Initiative qu\u00e9b\u00e9coise sur les biosimilaires\",\"datePublished\":\"2022-08-15T18:07:25+00:00\",\"dateModified\":\"2025-06-18T14:30:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/\"},\"wordCount\":1509,\"publisher\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/quebec-biosimilars.webp\",\"keywords\":[\"Biologics &amp; Biosimilars\",\"Politique\"],\"articleSection\":[\"Vid\u00e9o\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/\",\"url\":\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/\",\"name\":\"Initiative qu\u00e9b\u00e9coise sur les biosimilaires - Canadian Digestive Health Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/quebec-biosimilars.webp\",\"datePublished\":\"2022-08-15T18:07:25+00:00\",\"dateModified\":\"2025-06-18T14:30:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#primaryimage\",\"url\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/quebec-biosimilars.webp\",\"contentUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/quebec-biosimilars.webp\",\"width\":2000,\"height\":900,\"caption\":\"Two cartoon medicine bottles on white background\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cdhf.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Initiative qu\u00e9b\u00e9coise sur les biosimilaires\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cdhf.ca\/fr\/#website\",\"url\":\"https:\/\/cdhf.ca\/fr\/\",\"name\":\"Canadian Digestive Health Foundation\",\"description\":\"Serving Canadians with the latest digestive health news &amp; information\",\"publisher\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cdhf.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cdhf.ca\/fr\/#organization\",\"name\":\"Canadian Digestive Health Foundation\",\"url\":\"https:\/\/cdhf.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/cdhf.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png\",\"contentUrl\":\"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png\",\"width\":1154,\"height\":554,\"caption\":\"Canadian Digestive Health Foundation\"},\"image\":{\"@id\":\"https:\/\/cdhf.ca\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/CDHFdn\",\"https:\/\/x.com\/TheCDHF\",\"https:\/\/www.instagram.com\/cdhf_\/?hl=en\",\"https:\/\/www.youtube.com\/user\/CDHFtube\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cdhf.ca\/fr\/#\/schema\/person\/70d0733e8829dc3d75b25a0395127248\",\"name\":\"Sophie Allan\",\"description\":\"CDHF has done so much for me. I am so thankful. Please help me in raising much needed and well-deserved funds!\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Initiative qu\u00e9b\u00e9coise sur les biosimilaires - Canadian Digestive Health Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/","og_locale":"fr_FR","og_type":"article","og_title":"Initiative qu\u00e9b\u00e9coise sur les biosimilaires - Canadian Digestive Health Foundation","og_description":"Qu\u2019est-ce qui a chang\u00e9 dans la couverture des m\u00e9dicaments biologiques du Qu\u00e9bec? Le 18 mai 2021, le ministre de la Sant\u00e9 et des Services sociaux, Christian Dub\u00e9, a annonc\u00e9 que le gouvernement du Qu\u00e9bec lan\u00e7ait une initiative sur les biosimilaires qui consiste \u00e0 faire passer les patients des m\u00e9dicaments biologiques d&#8217;origine \u00e0 leurs versions biosimilaires. [&hellip;]","og_url":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/","og_site_name":"Canadian Digestive Health Foundation","article_publisher":"https:\/\/www.facebook.com\/CDHFdn","article_published_time":"2022-08-15T18:07:25+00:00","article_modified_time":"2025-06-18T14:30:34+00:00","og_image":[{"width":2000,"height":900,"url":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/quebec-biosimilars.webp","type":"image\/jpeg"}],"author":"Sophie Allan","twitter_card":"summary_large_image","twitter_creator":"@TheCDHF","twitter_site":"@TheCDHF","twitter_misc":{"Written by":"Sophie Allan","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#article","isPartOf":{"@id":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/"},"author":{"name":"Sophie Allan","@id":"https:\/\/cdhf.ca\/fr\/#\/schema\/person\/70d0733e8829dc3d75b25a0395127248"},"headline":"Initiative qu\u00e9b\u00e9coise sur les biosimilaires","datePublished":"2022-08-15T18:07:25+00:00","dateModified":"2025-06-18T14:30:34+00:00","mainEntityOfPage":{"@id":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/"},"wordCount":1509,"publisher":{"@id":"https:\/\/cdhf.ca\/fr\/#organization"},"image":{"@id":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#primaryimage"},"thumbnailUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/quebec-biosimilars.webp","keywords":["Biologics &amp; Biosimilars","Politique"],"articleSection":["Vid\u00e9o"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/","url":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/","name":"Initiative qu\u00e9b\u00e9coise sur les biosimilaires - Canadian Digestive Health Foundation","isPartOf":{"@id":"https:\/\/cdhf.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#primaryimage"},"image":{"@id":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#primaryimage"},"thumbnailUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/quebec-biosimilars.webp","datePublished":"2022-08-15T18:07:25+00:00","dateModified":"2025-06-18T14:30:34+00:00","breadcrumb":{"@id":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#primaryimage","url":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/quebec-biosimilars.webp","contentUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/08\/quebec-biosimilars.webp","width":2000,"height":900,"caption":"Two cartoon medicine bottles on white background"},{"@type":"BreadcrumbList","@id":"https:\/\/cdhf.ca\/fr\/quebec-biosimilars-initiative\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cdhf.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Initiative qu\u00e9b\u00e9coise sur les biosimilaires"}]},{"@type":"WebSite","@id":"https:\/\/cdhf.ca\/fr\/#website","url":"https:\/\/cdhf.ca\/fr\/","name":"Canadian Digestive Health Foundation","description":"Serving Canadians with the latest digestive health news &amp; information","publisher":{"@id":"https:\/\/cdhf.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cdhf.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/cdhf.ca\/fr\/#organization","name":"Canadian Digestive Health Foundation","url":"https:\/\/cdhf.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/cdhf.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png","contentUrl":"https:\/\/cdhf.ca\/wp-content\/uploads\/2022\/07\/CDHF_logo_sqstck_4line_CMYK.png","width":1154,"height":554,"caption":"Canadian Digestive Health Foundation"},"image":{"@id":"https:\/\/cdhf.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CDHFdn","https:\/\/x.com\/TheCDHF","https:\/\/www.instagram.com\/cdhf_\/?hl=en","https:\/\/www.youtube.com\/user\/CDHFtube"]},{"@type":"Person","@id":"https:\/\/cdhf.ca\/fr\/#\/schema\/person\/70d0733e8829dc3d75b25a0395127248","name":"Sophie Allan","description":"CDHF has done so much for me. I am so thankful. Please help me in raising much needed and well-deserved funds!"}]}},"_links":{"self":[{"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/posts\/4451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/comments?post=4451"}],"version-history":[{"count":0,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/posts\/4451\/revisions"}],"acf:post":[{"embeddable":true,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/cdhf-writers\/3779"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/media\/4448"}],"wp:attachment":[{"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/media?parent=4451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/categories?post=4451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdhf.ca\/fr\/wp-json\/wp\/v2\/tags?post=4451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}